ABBVIE

AbbVie and Genmab have received FDA approval for Epkinly as a treatment option for patients with relapsed or refractory follicular lymphoma.

The FDA has approved epcoritamab (Epkinly) in combination with rituximab and lenalidomide as the first bispecific antibody combination therapy for relapsed or refractory follicular lymphoma patients.

Johnson & Johnson announced the acquisition of Halda Therapeutics for $3.05 billion in cash to expand its oncology portfolio with oral, targeted therapies for solid tumors.

AbbVie announced Health Canada approval of a new 6-month 45mg strength of LUPRON DEPOT for advanced prostate cancer treatment, expanding dosing options to reduce administration burden.

Day One Biopharmaceuticals announced the acquisition of Mersana Therapeutics for $129 million upfront, with potential additional payments of $156 million tied to development milestones.

Genmab achieved 21% revenue growth to $2.66 billion in the first nine months of 2025, driven primarily by increased DARZALEX and Kesimpta royalties.

Roche will present 46 abstracts including 12 oral presentations at the 67th ASH Annual Meeting, demonstrating progress across hemophilia A, lymphoma, and multiple myeloma treatments.

The FDA is set to make five significant regulatory decisions in November 2025, including approvals for treatments targeting rare genetic disorders, multiple cancer types, and kidney disease.

Alector's investigational antibody latozinemab failed to slow disease progression in a 96-week Phase III trial for frontotemporal dementia caused by progranulin gene mutations.

Merck KGaA's antibody-drug conjugate precemtabart tocentecan (Precem-TcT) demonstrated a 31% objective response rate in heavily pre-treated colorectal cancer patients at 2.8mg/kg dose during Phase I trials.